US equities |
MU $934.27 ▲+0.00% INTC $92.07 ▲+0.00% SNDK $1,330.05 ▲+0.00% AMZN $243.79 ▲+0.00% NVDA $213.66 ▲+0.00% AAPL $348.91 ▲+0.00% GOOGL $283.82 ▲+0.00% AMD $566.42 ▲+0.00%
FinancialContent

Medexus Pharmaceuticals Inc (TSX:MDP)

5.040 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medexus Pharmaceuticals Inc

< Previous 1 2 3 Next >
News headline image
Medexus Eyes $175M GRAFAPEX Opportunity as Transplant Drug Gains Traction ↗
Medexus Pharmaceuticals (TSE:MDP) is prioritizing growth in hematology and oncology, with its recently launched GRAFAPEX treatment expected to be the company’s primary near-term revenue catalyst, Chief... 
Via MarketBeat
News headline image
Medexus Pharmaceuticals Q1 Earnings Call Highlights ↗
Medexus Pharmaceuticals (TSE:MDP) reported higher first-quarter fiscal 2027 revenue and adjusted EBITDA, supported by continued growth for GRAFAPEX and a stronger contribution from IXINITY, while... 
Via MarketBeat
Topics Earnings
News headline image
Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
News headline image
Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update
Annual revenue expected to exceed US$107 million for fiscal year ended March 31, 2023, an all-time record, including fiscal Q4 2023 revenue of at least US$28 million 
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
News headline image
Earnings Scheduled For October 28, 2021 ↗
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •... 
Via Benzinga
News headline image
Medexus Announces New License Deal for Topical Terbinafine
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
News headline image
Medexus Announces US$58.5 million in New Credit Facilities
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Pharmaceuticals Inc. (TSX: MDP) (OTCQX: MEDXF) Featured in Coverage of the 35th Annual Roth Conference
Via Investor Brand Network
News headline image
Medexus to Participate in 35th Annual Roth Conference
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
News headline image
Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
News headline image
Medexus Welcomes Two New Board Members
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
News headline image
Medexus Secures Public Reimbursement for Cuvposa® in Quebec
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
News headline image
Medexus Schedules Third Fiscal Quarter 2023 Conference Call
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
News headline image
Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business Update
Quarterly revenue expected to exceed US$28.5 million for quarter ended December 31, 2022, an all-time record 
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
News headline image
Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
News headline image
Medexus Schedules Second Quarter 2023 Conference Call
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
News headline image
Medexus Announces Preliminary Revenue Results for Second Fiscal Quarter 2023
Quarterly revenue expected to exceed US$27.0 million for quarter ended September 30, 2022, an all-time record 
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
News headline image
Medexus and MidCap Agree to Increase in MidCap’s Revolving Loan Commitment Amount
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
News headline image
How To Pick Dividend-Payers, Plus My Favorite One To Buy Now ↗
Ask income investors what they’re looking for, and one word is bound to come up. Predictability. Income investors want to know the money will keep showing up. 
Via Talk Markets
News headline image
Fitness App Hopes to Innovate, Keep Resolutions, by Paying To Complete a Workout Built for Your Level of Exercise ↗
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. It’s that... 
Via Benzinga
News headline image
Sidoti December Micro Cap Virtual Conference
Presentation Times Released for 75+ Presenting Companies Wednesday and Thursday, December 8-9, 2021 NEW YORK, NY / ACCESSWIRE / December 7, 2021 / Sidoti & Company, LLC has released the presentation... 
From Sidoti & Company, LLC
Via AccessWire
News headline image
The Rise And Fall Of MySpace ↗
Surprisingly, the site is still around and is being regularly filled with syndicated editorial content and its parent company seems to have recovered rather successfully: Viant went public this... 
Via Talk Markets
News headline image
Paul Rudd Named People's Sexiest Man Alive For 2021 ↗
People magazine has crowned actor Paul Rudd as its Sexiest Man Alive for 2021. What Happened: The announcement was made on Tuesday night’s broadcast of “The Late Show... 
Via Benzinga
News headline image
Making a Difference When You Invest? Medexus Says It Improves Lives ↗
Photo by Hernan Pauccara from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
News headline image
What Is IAC Planning With Its Acquisition of Magazine Publisher Meredith? ↗
A new media company is acquiring an old media company to continue its digital growth strategy. 
Via The Motley Fool
InvestorNewsBreaks – Nexstar Media Group Inc.’s (NASDAQ: NXST) Hartford-Based Station to Launch NEXTGEN TV
Via Investor Brand Network
News headline image
5 Value Stocks In The Communication Services Sector ↗
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
News headline image
Citi Considers Meredith As Fairly Valued, Downgrades To Neutral ↗
Citi analyst Jason Bazinet downgraded Meredith Corp (NYSE: MDP) to Neutral from Buy with a price target of $59, up from $54, implying priced at... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021 ↗
Upgrades UBS upgraded the previous rating for Northern Trust Corp (NASDAQ: 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Friday ↗
Barclays cut the price target on Constellation Brands, Inc. (NYSE: 
Via Benzinga
< Previous 1 2 3 Next >